Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first‐line treatment for patients with advanced renal cell carcinoma: Real‐world experience in Japan
International Journal of Urology · 2023
DOI: 10.1111/iju.15256 ↗Kurz gefasst
Editorial in der Zeitschrift International Journal of Urology, 2023. Verfasst von Tsunenori Kondo. Beteiligte Einrichtung: Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Tsunenori Kondo received honoraria from Pfizer, MSD, Takeda Pharmaceuticals, and Ono Pharmaceutical.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.
Zitieren
APA
Kondo, T. (2023). Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first‐line treatment for patients with advanced renal cell carcinoma: Real‐world experience in Japan. International Journal of Urology. https://doi.org/10.1111/iju.15256
Vancouver
Kondo T. Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first‐line treatment for patients with advanced renal cell carcinoma: Real‐world experience in Japan. International Journal of Urology. 2023. doi:10.1111/iju.15256
BibTeX
@article{Kondo2023,
author = {Kondo, Tsunenori},
title = {Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first‐line treatment for patients with advanced renal cell carcinoma: Real‐world experience in Japan},
journal = {International Journal of Urology},
year = {2023},
doi = {10.1111/iju.15256}
}
EUVIMED